Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms

Breast Cancer Research and Treatment

Volumn 145, Issue 3, 2014, Pages 697-705

  Drukker, C A ^a   Nijenhuis, M V ^a   Bueno De Mesquita, J M ^a   Retel V P ^a   Van Harten, W H ^a   Van Tinteren, H ^a   Wesseling, J ^a   Schmidt, M K ^a   Van'T Veer, L J ^a,b,c   Sonke, G S ^a   Rutgers, E J T ^a   Van De Vijver, M J ^a,d   Linn, S C ^a,e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Agendia NV   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

70 Gene signature; Adjuvant systemic treatment; Breast cancer; Clinical guidelines; Prognosis prediction

Indexed keywords

70 GENE SIGNATURE; ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT RECURRENCE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MASTECTOMY; MOLECULAR DIAGNOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADOLESCENT; BREAST NEOPLASMS; DECISION SUPPORT SYSTEM; FORECASTING; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROCEDURES; REGRESSION ANALYSIS; RISK; TUMOR RECURRENCE; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; ALGORITHMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; FEMALE; FORECASTING; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REGRESSION ANALYSIS; RISK; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901589420     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2954-2     Document Type: Article

References (20)

1. D'Eredita' G, Giardina C, Martellotta M, Natale T, Ferrarese F (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591-596
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 19:3817-3827
3. Integraal Kankercentrum Nederland: NABON richtlijn mammacarcinoom (2012)
4. Kwaliteitsinstituut voor de Gezondheidszorg CBO VvlK: Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom (2004) Richtlijn Behandeling van het Mammacarcinoom 46-70
5. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725
6. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365
7. Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkas K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Begin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD (2012) PREDICT plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 107:800-807
8. Mook S, van't Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK (2011) Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:585-597
9. Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC (2011) Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann Oncol 22:2021-2030
10. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991
11. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192
12. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13:477-493
13. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
14. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
15. Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8:1079-1087
16. Drukker CA, Bueno-de-Mesquita JM, Retel VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 133:929-936
17. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489-492
18. Drukker CA, van den Hout HC, Sonke GS, Brain E, Bonnefoi H, Cardoso F, Goldhirsch A, Harbeck N, Honkoop AH, Koornstra RH, van Laarhoven HWM, Portielje JEA, Schneeweiss A, Smorenburg CH, Stouthard J, Linn SC, Schmidt MK (2014) Risk estimations and treatment decisions in early stage breast cancer; agreement among oncologists and the impact of the 70-gene signature. Eur J Cancer 50(6):1045-1054
19. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127-2132
20. Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ (2010) The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 21:40-47